Related Experiment Videos

Novel agents: clinical trial design

A R Tan1, S M Swain

  • 1Cancer Therapeutics Branch, National Cancer Institute, Bethesda, MD 20889, USA.

Seminars in Oncology
|November 14, 2001
PubMed

Insights

Developing targeted anticancer drugs offers promise but faces challenges. This study outlines optimal methods for evaluating these novel molecularly targeted anticancer agents and their clinical trial designs.

Area of Science:

  • Oncology
  • Pharmacology
  • Clinical Trials

Background:

  • Molecularly targeted anticancer agents represent a significant advancement in cancer therapy.
  • Evaluating the efficacy and safety of these novel drugs presents unique challenges for researchers.

Purpose of the Study:

  • To provide an overview of the difficulties in developing targeted anticancer agents.
  • To describe optimal clinical research methodology for determining the efficacy of these compounds.

Main Methods:

  • Review of challenges in preclinical model creation for target assessment.
  • Discussion on validation of surrogate endpoints for novel anticancer drugs.
  • Analysis of effective clinical trial designs for targeted therapies.

Main Results:

  • Identified key challenges in evaluating molecularly targeted anticancer agents.
  • Highlighted the need for appropriate models and validated surrogate endpoints.
  • Emphasized the importance of effective clinical trial designs.

Conclusions:

  • Overcoming evaluation challenges is crucial for advancing targeted anticancer drug development.
  • Optimal clinical research methodology is essential for accurately determining drug efficacy.
  • This work provides a framework for future research in targeted cancer therapy evaluation.

Related Concept Videos